Approval · Notice of Compliance 26741 · 2021
REPLAGAL: Notice of Compliance 26741
Issued September 28, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26741
- Date
- September 28, 2021
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REPLAGAL | Not yet assigned | — |
Medicinal ingredients
- AGALSIDASE ALFA 1 MG per ML